

May 18, 2012

Application filed for Overactive Bladder Drug HOB-294  
(Oxybutynin Hydrochloride, Transdermal Therapeutic Formulation)

Hisamitsu Pharmaceutical Co., Inc. (President and CEO:Hirotaka Nakatomi) announced that it has filed an application for new drug approval with Ministry of Health, Labour and Welfare for use of Overactive Bladder Drug HOB-294 (Oxybutynin Hydrochloride, Transdermal Therapeutic Formulation).

HOB-294 is a transdermal therapeutic formulation used to treat “overactive bladder,” which causes an urge to urinate and frequent urination. We have domestically promoted the development with expectation of the persistence of drug efficacy by stably maintaining drug levels in the blood.

In the future, we aim to acquire for manufacturing and marketing approval during fiscal 2013.